Om Saniona AB (publ)
Saniona AB (publ), a research and development company, engages in the development of drugs for diseases of the central nervous system and eating disorders in Denmark. It has a portfolio of various drug candidates in pre-clinical and clinical stages. The company's products include Tesofensine, a triple monoamine reuptake inhibitor, which is in Phase III clinical trials to treat obesity; Tesomet, a fix-dose combination of tesofensine and metoprolol that is in Phase II clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity; NS2359, a triple monoamine reuptake inhibitor that is in Phase II clinical trial for cocaine addiction; and CAD-1883 that is in Phase II clinical trial for tremor and spinocerebellar ataxia. It is also developing SAN711 for chronic itching and neuropathic pain; Boehringer Ingelheim program for schizophrenia; IK program for inflammatory bowel diseases; Nicotinic-a6 program for parkinson's diseases; Kv7 program for pain, epilepsy, and urinary incontinence; and SAN903 for autoimmune disorders. Saniona AB (publ) was founded in 2011 and is headquartered in Ballerup, Denmark.
Læs mere